Alumis Inc Total Liabilities
Alumis Inc total liabilities. Based on the latest financial reports, Alumis Inc (ALMS) has total liabilities worth $108.46 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Alumis Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Alumis Inc (2022–2025)
Total liabilities of Alumis Inc from 2022 to 2025. This chart illustrates how Alumis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ALMS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Alumis Inc Competitors by Total Liabilities
The table below lists competitors of Alumis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SP Group A/S
CO:SPG
|
Denmark | Dkr2.23 Billion |
|
Cosmoam&T
KO:005070
|
Korea | ₩271.95 Billion |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
USA | $537.78 Million |
|
Morguard Corporation
TO:MRC
|
Canada | CA$7.15 Billion |
|
TrustCo Bank Corp NY
NASDAQ:TRST
|
USA | $5.84 Billion |
|
Fujian Guanfu Modern Household Wares Co Ltd
SHE:002102
|
China | CN¥3.28 Billion |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
Thailand | ฿3.28 Billion |
|
Lontium Semiconductor Corp. A
SHG:688486
|
China | CN¥67.61 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Alumis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Alumis Inc.
Liquidity & Leverage Metrics
Alumis Inc Total Liabilities Ratios Explained
Alumis Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alumis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alumis Inc (2022–2025)
The table below shows the annual total liabilities of Alumis Inc from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $110.64 Million | +36.78% |
| 2024-12-31 | $80.89 Million | -81.14% |
| 2023-12-31 | $428.87 Million | +41.35% |
| 2022-12-31 | $303.41 Million | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more